The groundbreaking approach of this peptide represents a significant breakthrough in the handling of type 2 diabetes. Distinct from existing therapies, tirzepatide affects two pathways – glucagon-like peptide-1 (GLP-1) and GIP – resulting in greater glucose control and potential weight reduction.